ABSTRACT. In this study, the experimental model of Wigglesworth was used to limit the maternal blood supply to the rat fetus and induce intrauterine growth retardation. The associated changes in plasma somatomedin activity, insulin, glucose, and cartilage metabolic activity are reported. The mean body weight (f SEM) of 108 fetuses in ligated uterine horns was significantly lower than that of 146 control fetuses (ligated, 2820 f 50 mg; control, 3180 
costal cartilage in basal culture medium was significantly lower in growth-retarded fetuses than in controls. Plasma somatomedin activity measured by fetal rat cartilage bioassay was significantly lower in growth-retarded than in control fetuses ( p < 0.001). The growth-retarded fetuses were relatively hypoinsulinemic and hypoglycemic compared to control animals. These studies suggest that nutrient supply may become a limiting factor in the release of insulin and the circulating levels of somatomedin activity in the rat fetus, and hence in its growth. (Pediatr Res 18:llOO-1104)
Abbreviation

MSA, multiplication-stimulating activity
The growth hormone-dependent peptide growth factors, the somatomedins, have a major role in the growth and development of skeletal and somatic tissues in postnatal life (1). Somatomedins also are present in the fetus and a positive correlation between circulating levels and fetal body size led us and others to hypothesize that somatomedins providean important anabolic stimulus to development in utero (2) (3) (4) (5) . However, the factors controlling circulating levels of somatomedins in the fetus are not understood. Growth hormone does not appear to be important since decapitation of the fetal rabbit and hypophysectomy of the lamb in utero did not lower somatomedin bio-and radioreceptor activity, and did not seriously retard body growth (6, 7) . Nutritional composition and availability influenced postnatal somatomedin release, over-riding the actions of growth hormone, and nutrient availability could regulate fetal growth through somatomedin action (8) . However, it is not possible to investigate nutrition without considering the release and action of insulin which also has been postulated to be a major anabolic hormone in utero (9) .
In this study, the experimental model of Wigglesworth (10) was used to limit the maternal blood supply to the rat fetus. This was reported to result in a relative intrauterine growth retardation accompanied by fetal hypoglycemia and hypoinsulinemia, but the outcome in terms of fetal survival and morphometry has been extremely variable (10) (11) (12) . The purpose of our experiments was to perform a detailed statistical analysis of the validity of the model and to investigate the relationship between circulating levels of somatomedin bioactivity, insulin and glucose, endogenous cartilage metabolic activity, and body and organ size during experimental fetal growth retardation.
MATERIALS AND METHODS
Animals. Pregnant Wistar rats of approximately 250 g weight were taken from the departmental colony and mated overnight. The day of mating was confirmed by the appearance of the vaginal plug and was designated day 1 of gestation. Animals had free access to food and water. On day 17, a laparotomy was performed under ether anesthesia via a midline incision. The uterine horn containing the larger number of fetuses was selected, and the uterine artery and vein on that side were occluded by ligation at the cervix. The other uterine horn was left as a control and the maternal incision closed. On the morning of day 2 1 the rats were killed painlessly and all fetuses were delivered immediately by cesarian section. As each fetus was exposed, a deep incision was made in the axillary region and blood was collected on ice while the placenta and umbilicus were still intact. The latter point is of importance since blood glucose and insulin values can alter rapidly in the rat fetus especially following severance of the umbilical cord (13) . Blood from all animals within a single uterine horn, either ligated or control, was pooled before the centrifugation and separation of plasma which was stored at -20" C. After noting the position of each fetus within the uterus, they were weighed to an accuracy of 1 mg and the nose-tail length was measured by ruler to the nearest millimeter. Liver weight was recorded to an accuracy of 1 mg before the removal of costal cartilage.
Cartilage incubation. Costal cartilage was dissected from every fetus within a ligated uterine horn, and from an equivalent number of fetuses from the nonligated horn at comparable implantation positions. When the control fetuses were fewer all fetuses within the litter were used. Cartilage incubations were performed in a Krebs phosphosaline buffer enriched with amino acids (14) , and supplemented with penicillin (100 microunits/ ml) and streptomycin (100 pg/ml (14) . Results are expressed as the mean of duplicate incubations in counts/min per mg weight cartilage. Hormone assay. Fetal rat plasma somatomedin activity was measured by the fetal rat costal cartilage bioassay system described earlier (14, 15) . Pooled costal cartilage was taken from the control fetuses in the nonligated uterine horn. The assay utilizes the incorporation of [35S]sulfate in vitro and results were calculated as relative potencies compared to standard adult rat plasma of defined potency 1 .O unit/ml. Insulin levels in the fetal rat were measured by radioimmunoassay as described previously (15) . All samples were included within a single assay. Blood glucose was measured by a glucose oxidase technique (1 6).
RESULTS
Technical success. Of 41 pregnant rats submitted to surgery, 37 animals retained one or more fetuses within the ligated uterine horn. Of these, six rats retained a single fetus, 10 retained two fetuses, 11 retained three fetuses, four retained four fetuses, four retained 5 fetuses, and two retained six fetuses. The mean ( f SEM) number of surviving fetuses per litter in the ligated and nonligated horns was 2.9 + 0.2 (range, 1-6) and 3.9 f 0.2 (range, 1-8), respectively. In three animals, all experimental fetuses were resorbed and in one rat extensive anastomosis of blood vessels occurred around the ligation. This animal was excluded from the experiment. Of 2 17 fetuses present at surgery in the ligated horns, 109 (49%) had been resorbed by day 21, while of 148 fetuses within the control uterine horns only 2 (1%) were resorbed. Resorption and intrauterine growth retardation were not limited to sites close to the ligature.
Body size and cartilage metabolic activity. The mean body weight (+SEM) of 108 fetuses in the ligated uterine horn was significantly lower than that of 146 control fetuses when assessed by t test for mean values (ligated, 2820 f 50 mg; control, 3 180 + 50 mg; p < 0.001), as was nose-tail tip length (ligated, 55.6 + 0.4 mm; control, 59.4 + 0.3 mm; p < 0.001) and liver weight (ligated, 222 f 5 mg; control, 274 f 5 mg; p < 0.001). Liver weight expressed as a percentage of total body weight was significantly lower in fetuses from the ligated horn than in control animals (ligated, 7.96 f O.11%, control, 8.91 f 0.09%, p < 0.001). The findings were confirmed by rigorous multivanate analysis of variance taking account of the between and within litter variation and the implantation site of the fetus within the uterus (Table I) . Fetuses were numbered chronologically within each uterine horn, the first animal being that nearest the ovary and the last that nearest the cervix. When compared by paired analysis, a significant comparative growth retardation existed between fetuses in the ligated and control horns in positions 1 to 3, and was most pronounced in position 3 as seen by the t values and a percentage reduction in body weight of 18%. However, within each uterine horn, for both ligation and control, mean body weight did not differ with the site of implantation and the mean weight of fetuses did not alter with litter size.
The mean (fSD) uptake of [35S]sulfate by costal cartilage in basal culture medium was significantly lower in fetuses from the ligated horn than in controls (ligated, 1808 f 686 cpm/mg; control, 2242 f 908; p < 0.005 by paried t test for 86 pairs of animals). In the presence of normal rat plasma (lo%, v/v), the incorporation of isotope was stimulated to a similar extent above basal levels in cartilage from both groups of animals, and the resulting incorporation did not differ significantly between groups (ligated, 8905 rt 3244; control, 9280 f 3828). Isotope uptake in basal culture medium showed positive correlation with body weight, length, and liver weight when test and control fetuses were considered together but this was dependent on the site of implantation within the uterus, being significant at positions 3 ( r = 0.50 or better; n = 54; p < 0.05) and 4 ( r = 0.70 or better; n = 12; p < 0.05) only. This was possibly due to the relative growth retardation being greatest in these positions leading to a wide distribution of parameters of size.
Plasma somatomedin activity. Somatomedin activity (mean + SD), measured by fetal rat cartilage assay, in pooled plasma from all fetuses in the ligated uterine horn of each litter was significantly lower than that found in pooled plasma from all fetuses in the control horn (ligated, 0.62 + 0.22 unit/ml; control, 0.85 f 0.28 unit/ml; p < 0.001 by paired t test for 3 1 litters). When all fetuses were considered, the levels of somatomedin activity in pooled plasma from animals in each horn correlated positively with body weight ( r = 0.37; n = 65; p = 0.01), body length ( Fig.   1 ) and liver weight (r = 0.41; n = 65; p < 0.001). In these calculations, the mean uterine horn values for parameters of body size were employed for each group. For fetuses from the ligated horn alone, significant correlations were present with body weight ( r = 0.48; n = 34), length ( r = 0.45; n = 34) and liver weight (r = 0.44; n = 34; p < 0.01), but no significant correlations existed for control animals alone with any parameter (r = 0.12-0.14; p < 0.1). No significant correlation existed between plasma levels of insulin and somatomedin ( p < 0.1) for ligated or control animals considered either separately or together ( n = 46).
Insulin and glucose levels. Insulin and glucose were measured in pooled plasma from all fetuses in either the ligated or control horns for each litter where sufficient plasma was available. Fetuses from the ligated uterine horn were relatively hypoinsuli- 
DISCUSSION
Several authors have described the relative fetal growth retardation resulting from ligatipn of the uterine artery and vein in one uterine horn of the pregnant rat (10-12, 17) but the distribution of fetal size described by Wigglesworth has been difficult to reproduce. A comprehensive analysis of the model with reference to the site of implantation within the uterus and the considerable between-litter variation has been lacking. Wigglesworth concluded that where several fetuses remained in the ligated uterus at least 4 days after surgery there was a graded decrease in size between the fetuses at the ovarian and cervical extremes (10) . At the ovarian end of the uterus fetuses were of comparable size to those in the control horn while at the cervical end fetuses were commonly dead or resorbed.
Our analysis differs from this account in several ways. Firstly, a statistically significant relative growth retardation was found between fetuses in ligated and control horns at the implantation site nearest to the ovary, although this was more pronounced at the second and third furthest sites from the ovary compared to the corresponding control fetus. Secondly, fetal resorption was found at every implantation site in the uterus and a live fetus could be present between two resorbed animals. Although there was a general decrease in fetal body size in the ligated horn from ovary to cervix, this was not statistically significant. We therefore conclude that the fetal growth retardation encountered here was a more general phenomenon throughout the ligated uterus than that described previously, and that when using this experimental model to identify changes in circulating fetal hormone levels it is acceptable to take a pooled sample of blood from all surviving, fetuses within a uterine horn.
Assessment of skeletal growth by the measurement of nosetail tip length showed that skeletal tissues were relatively less affected than body weight, but the incorporation of [35S]sulfate in vitro by cartilage from growth-retarded fetuses was significantly lower than that in control animals. This is unlikely to represent a general decrease in tissue anabolism in fetuses from the ligated horn since isotope uptake was enhanced in cartilage from both growth-retarded and control animals when exposed to a plasma challenge, demonstrating that the cellular mechanisms of hormone action remained intact. The precise origin of growth retardation in the Wigglesworth model is not known but could involve placental ischemia, a reduced transplacental passage of nutrients, or a reduced oxygen availability to the fetus.
Bioassayable somatomedin activity was reduced in fetuses from the ligated uterine horn and was positively correlated to parameters of body size. The bioassay used utilizes fetal rat cartilage and detects the sulfation factor activity present in fetal plasma. This was greater than that detectable in a bioassay based on postnatal porcine cartilage suggesting that additional sulfation factor activity was present in the rat fetus to which postnatal cartilage was refractory (14) . Fetal rat cartilage also detected substantially more sulfation factor activity in plasma from hypophysectomized rats compared to normal rat plasma than did postnatal cartilage, further suggesting that the spectrum of tissue sensitivity to growth factors differs between fetal and postnatal life. An analogous report by Sara and Hall (3) found that a radioreceptor assay using human fetal brain cell membranes detected somatomedin activity in human fetal serum not measurable using a conventional radioimmunoassay for somatomedin A. Purified peptide growth factors including the two somatomedins, somatomedin-C and MSA 11, promoted radiolabeled thymidine incorporation by fetal rat cartilage in vitro (1 8, 19 ). MSA I1 promoted the uptake of radioactive sulfate in this system but somatomedin-C was without effect.
Since the physiologically important somatomedin peptides in the fetal rat have not yet been characterized and identified, we have maintained that a bioassay appropriate for species and gestational age is at least as relevant as more specific assays for particular somatomedins purified from adult serum or tissues. Using the latter, radioimmunoassayable serum insulin-like growth factor I (somatomedin-C) and somatomedin A were reported to be lower than adult values in the fetal rat (20, 21) while MSA measured by radioreceptor or immunoassay was many times greater in the fetal and neonatal rat than in later life (20, 22) . When detected by a postnatal rat cartilage bioassay, somatomedin activity was considerably lower than adult levels in fetal rat serum (23) . While the fetal rat cartilage bioassay may detect so far uncharacterized fetal growth factors, it does provide a sensitive indicator of at least one purified somatomedin, MSA 11, found by specific assay to be elevated in the fetal rat circulation. The positive correlation between somatomedin bioactivity and fetal size suggests that its measurement is of biological relevance.
During acute postnatal malnutrition, inhibiting factors were detected in serum which interfered with the action of somatomedins in biological assay systems (8) . Since in the fetal cartilage assay-parallel dose responses were always obtained between test plasma from growth-retarded fetuses and the standard rat plasma, there was no evidence for the presence of inhibitory factors to cartilage sulfation. The present results support those of Foley et al. (24) who found somatomedin levels in the cord blood of the human growth-retarded infant to be lower than those of normally grown infants.
While the present study establishes a reduced somatomedin activity and cartilage metabolic activity associated with fetal growth retardation in the rat, it does not identify the mechanisms responsible for this observation. It must be considered whether the growth retardation and associated endocrine changes represent a delay of fetal maturation. The endocrinology may therefore be appropriate for the development of the fetus. This is supported by the finding of Kollee et al. (25) that there was a delay in the development of gluconeogenic enzymes in growthretarded rats in the same experimental model. However comparison with our own published data for the growth of the fetal Wistar rat (14) shows that, in terms of body weight and length, fetal development was delayed by less than 2 days gestation. Between days 19 and 2 1 of gestation, there was no alteration in cartilage sulfate uptake in vitro or in bioassayable somatomedin activity, measured by either fetal rat or postnatal porcine cartilage assay, in the normal rat fetus. The reduced circulating somatomedin activity in growth-retarded fetuses may therefore reflect an adaptive change. The ability to produce somatomedin was shown to be a property of many fetal tissues (26) but the liver, because of its size, is likely to be the major source of somatomedin activity in the circulation. Somatomedins, like insulin and growth hormone, do not cross the placenta from mother to fetus (27) . The mechanism of action of somatomedins in fetal life is unsure. A widespread production of somatomedins by fetal tissues may represent a largely paracrine system of growth control in which case those peptides contributing to plasma somatomedin activity may only be an indirect indicator of tissue anabolism. A reduced circulating somatomedin activity during intrauterine growth retardation could result from a direct influence of nutrient availability on somatomedin release throughout the body. Alternatively, the association between nutrition and somatomedins could be mediated via the endocrine system. Growth hormone has a major role in the control of somatomedin production after birth but is thought to be unnecessary for the maintenance of growth and somatomedin activity in fetal life (6, 7) . Although the limited availability of plasma precluded the measurement of fetal growth hormone in this study, it has previously been reported that circulating levels were raised in growth-retarded rat fetuses compared to control animals in the Wigglesworth model (28) .
Although insulin is often postulated to act as a growth-promoting hormone in fetal life, there is little evidence that it is directly mitogenic at physiological concentrations. Insulin had no direct action at physiological concentrations on the uptake of either ['Hlthymidine or ["S]sulfate by fetal rat costal cartilage in vitro (2, 18) . The administration of pharmacological concentrations of insulin to the fetal rat and monkey led to enhanced body growth (29, 30) , but this may have been mediated by an increase in circulating somatomedin since somatomedin activity was enhanced in the fetal rabbit and pig following treatment with insulin in utero (3 1, 32) . In the postnatal rat, insulin was shown to stimulate somatomedin production directly from liver during perfusion and tissue slice incubation (33, 34) . The induction of hyperglycemia in the fetal rat in late gestation resulted in enhanced levels of circulating insulin and increased body weight (35) and raised circulating somatomedin activity (36) .
Positive relationships therefore exist between fetal body size and the levels of insulin and somatomedin in the blood as seen from the significant correlation between body weight or length and somatomedin activity in the present experiments, and our previous findings that immunoassayable levels of insulin Cpeptide in amniotic fluid were reduced compared to control animals and showed positive correlation with body weight in the Wigglesworth model (37) . These studies suggest that nutrient supply may become a limiting factor in the release of both insulin and somatomedin in the rat fetus, and hence in its growth.
